In early-phase human trials, single-dose NTLA-2002 produced a dose-dependent reduction in plasma kallikrein (67% reduction at 25 mg, 84% at 50 mg, and 95% at 75 mg), accompanied by a 95% overall reduction in the mean frequency of HAE attacks[1,13]. The gene discussed is KLK4; the disease is hereditary angioedema.